- Home
- HPAI vs AMRN Comparison
HPAI vs AMRN Comparison
Compare HPAI & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPAI
- AMRN
- Stock Information
- Founded
- HPAI 2023
- AMRN 1989
- Country
- HPAI Singapore
- AMRN Ireland
- Employees
- HPAI N/A
- AMRN N/A
- Industry
- HPAI
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- HPAI
- AMRN Health Care
- Exchange
- HPAI NYSE
- AMRN Nasdaq
- Market Cap
- HPAI 189.4M
- AMRN 234.4M
- IPO Year
- HPAI N/A
- AMRN 1993
- Fundamental
- Price
- HPAI $4.85
- AMRN $0.59
- Analyst Decision
- HPAI
- AMRN Hold
- Analyst Count
- HPAI 0
- AMRN 3
- Target Price
- HPAI N/A
- AMRN $1.00
- AVG Volume (30 Days)
- HPAI 18.6K
- AMRN 663.0K
- Earning Date
- HPAI 11-12-2024
- AMRN 10-30-2024
- Dividend Yield
- HPAI N/A
- AMRN N/A
- EPS Growth
- HPAI N/A
- AMRN N/A
- EPS
- HPAI N/A
- AMRN N/A
- Revenue
- HPAI $21,307,683.00
- AMRN $264,779,000.00
- Revenue This Year
- HPAI N/A
- AMRN N/A
- Revenue Next Year
- HPAI N/A
- AMRN N/A
- P/E Ratio
- HPAI $26.56
- AMRN N/A
- Revenue Growth
- HPAI 377.09
- AMRN N/A
- 52 Week Low
- HPAI $3.07
- AMRN $0.56
- 52 Week High
- HPAI $14.74
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- HPAI N/A
- AMRN 45.80
- Support Level
- HPAI N/A
- AMRN $0.56
- Resistance Level
- HPAI N/A
- AMRN $0.59
- Average True Range (ATR)
- HPAI 0.00
- AMRN 0.02
- MACD
- HPAI 0.00
- AMRN 0.00
- Stochastic Oscillator
- HPAI 0.00
- AMRN 36.78
About HPAI HELPORT AI LTD
Helport AI Ltd is a AI technology company based in Singapore dedicated to serving enterprises' customer contact centers with intelligent products, solutions, and a digital platform. Its software, Helport AI Assist (AI Assist), provides tailored AI-powered guidance and oversight for contact center interactions and customer experience, with functions including Agent Assistant, Quality Assurance (QA) Assistant, Supervisor Assistant, and Knowledge Base Assistant.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.